John Simes
- Oncology top 0.5%
- Colorectal Cancer Treatments and Studies 36
- Cancer Treatment and Pharmacology 16
- Gastroenterology top 0.5%
- Surgery top 0.5%
- Lipoproteins and Cardiovascular Health 23
- Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes 31
-
- Glioma Diagnosis and Treatment 23
-
- Health Systems, Economic Evaluations, Quality of Life 21
-
- Cancer Genomics and Diagnostics 17
-
- Acute Myocardial Infarction Research 15
- Co-authors
- Val GebskiJohn ZalcbergB. Mark SmithersBryan BurmeisterKerwyn FooDavina GhersiAndrew TonkinWendy Hague
- Cited by
- OncologyGastroenterologySurgery
- Journals
- Journal of Clinical Oncology (45 papers)Annals of Oncology (13 papers)Circulation (10 papers)
- Partner nations
- AustraliaNew ZealandCanada
In The Last Decade
John Simes
168 papers receiving 8.8k citations
Hit Papers
Peers
Comparison fields: 5 of 184
- Oncology 2.9k
- Gastroenterology 569
- Surgery 3.7k
- Pulmonary and Respiratory Medicine 2.5k
- Statistics, Probability and Uncertainty 547
Countries citing papers authored by John Simes
This map shows the geographic impact of John Simes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Simes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Simes more than expected).
Fields of papers citing papers by John Simes
This network shows the impact of papers produced by John Simes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Simes. The network helps show where John Simes may publish in the future.
Co-authorship network
The 25 scholars most cited alongside John Simes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 1 | |
| 2 | 2024 | 1 | |
| 3 | 2023 | 2 | |
| 4 | 2023 | 1 | |
| 5 | 2023 | 1 | |
| 6 | 2021 | 6 | |
| 7 | 2020 | 5 | |
| 8 | A RANDOMIZED PHASE II TRIAL OF VELIPARIB (V), RADIOTHERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS (PTS) WITH UNMETHYLATED MGMT (uMGMT) GLIOBLASTOMA (GBM): THE VERTU STUDY | 2019 | 1 |
| 9 | ATHENA (GOG-3020/ENGOT-ov45): A randomised, double-blind, placebo-controlled, phase 3 study of rucaparib plus nivolumab following front-line platinum-based chemotherapy in ovarian cancer | 2018 | 1 |
| 10 | 2018 | 19 | |
| 11 | 2017 | 10 | |
| 12 | 2016 | 203 | |
| 13 | 2012 | 19 | |
| 14 | Study protocol: The Early Prevention of Obesity in CHildren (EPOCH) Collaboration - an Individual Patient Data Prospective Meta-Analysis | 2010 | 9 |
| 15 | The Early Prevention of Obesity in CHildren (EPOCH) collaboration : an individual patient data prospective meta-analysis | 2010 | 0 |
| 16 | 2003 | 35 | |
| 17 | Pravastatin reduces the high rate of atherothrombotic complications in coronary heart disease patients with intermittent claudication | 2001 | 1 |
| 18 | Acute Coronary Syndrome Patients Benefit from Platelet Glycoprotein IIb/IIIa Inhibition as Part of an Initially Medical Treatment Strategy: Results of a Meta-Analysis of Phase III Randomized Trials | 2001 | 0 |
| 19 | Mortality reduction with accelerated tissue plasminogen activator is explained by early coronary patency | 1993 | 2 |
| 20 | Comparison of clinical outcomes in the US and non-US countries participating in GUSTO | 1993 | 1 |
About John Simes
John Simes is a scholar working on Oncology, Genetics and Cancer Research, having authored 172 papers that have together received 9.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (36 papers), Gastric Cancer Management and Outcomes (31 papers), Glioma Diagnosis and Treatment (23 papers), Lipoproteins and Cardiovascular Health (23 papers), Health Systems, Economic Evaluations, Quality of Life (21 papers), Cancer Genomics and Diagnostics (17 papers), Cancer Treatment and Pharmacology (16 papers) and Acute Myocardial Infarction Research (15 papers). The work is most often cited by research in Oncology (2.9k citations), Gastroenterology (569 citations) and Surgery (3.7k citations). John Simes has collaborated with scholars based in Australia, New Zealand and Canada. Frequent co-authors include Val Gebski, John Zalcberg, B. Mark Smithers, Bryan Burmeister, Kerwyn Foo, Davina Ghersi, Andrew Tonkin, Wendy Hague, Kate Wilson and Michael J. Solomon. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Circulation, Cochrane Database of Systematic Reviews and Neuro-Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.